MorphoSys grants I-Mab rights to CD38 mAb in China

MorphoSys AG (Xetra:MOR; Pink:MPSYY) granted I-Mab Biopharma (Shanghai, China) exclusive development and commercial rights to MOR202 in China, Taiwan, Hong Kong and Macau. MorphoSys will

Read the full 255 word article

User Sign In